APA

Malorni L., Curigliano G., Minisini A. M., Cinieri S., Tondini C. A., D'Hollander K., Arpino G., Bernardo A., Martignetti A., Criscitiello C., Puglisi F., Pestrin M., Sanna G., Moretti E., Risi E., Biagioni C., McCartney A., Boni L., Buyse M., Migliaccio I., Biganzoli L. & Di Leo A. (20191223). Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial. : Annals of oncology : official journal of the European Society for Medical Oncology.

Chicago

Malorni L, Curigliano G, Minisini A M, Cinieri S, Tondini C A, D'Hollander K, Arpino G, Bernardo A, Martignetti A, Criscitiello C, Puglisi F, Pestrin M, Sanna G, Moretti E, Risi E, Biagioni C, McCartney A, Boni L, Buyse M, Migliaccio I, Biganzoli L and Di Leo A. 20191223. Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial. : Annals of oncology : official journal of the European Society for Medical Oncology.

Harvard

Malorni L., Curigliano G., Minisini A. M., Cinieri S., Tondini C. A., D'Hollander K., Arpino G., Bernardo A., Martignetti A., Criscitiello C., Puglisi F., Pestrin M., Sanna G., Moretti E., Risi E., Biagioni C., McCartney A., Boni L., Buyse M., Migliaccio I., Biganzoli L. and Di Leo A. (20191223). Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial. : Annals of oncology : official journal of the European Society for Medical Oncology.

MLA

Malorni L, Curigliano G, Minisini A M, Cinieri S, Tondini C A, D'Hollander K, Arpino G, Bernardo A, Martignetti A, Criscitiello C, Puglisi F, Pestrin M, Sanna G, Moretti E, Risi E, Biagioni C, McCartney A, Boni L, Buyse M, Migliaccio I, Biganzoli L and Di Leo A. Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial. : Annals of oncology : official journal of the European Society for Medical Oncology. 20191223.